Anti-Mouse CD11c PE 100 ug
- Known as:
- Antibody toMouse CD11c PE 100 ug
- Catalog number:
- 12-0114-82
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD11c 100
Related genes to: Anti-Mouse CD11c PE 100 ug
- Gene:
- ITGAX NIH gene
- Name:
- integrin subunit alpha X
- Previous symbol:
- CD11C
- Synonyms:
- CD11c
- Chromosome:
- 16p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-08-15
- Date modifiied:
- 2015-12-15
Related products to: Anti-Mouse CD11c PE 100 ug
Related articles to: Anti-Mouse CD11c PE 100 ug
- Integrin alpha X (ITGAX, CD11c) functions as a leukocyte adhesion molecule vital for immune cell activation, antigen presentation, and inflammatory responses. However, the expression profile, clinical relevance, immunoregulatory functions, and underlying mechanisms of ITGAX in clear cell renal cell carcinoma (ccRCC) remain incompletely elucidated. - Source: PubMed
Publication date: 2026/07/02
Chen XuehuaLin ZongrongZhang RanranXie HaominKong WeiyiFu ZhenyangPei Xiaojuan - Time-restricted feeding (TRF) is a promising dietary strategy to improve the metabolic parameters associated with obesity, but its potential benefits in obesity linked to nighttime light exposure remain largely unclear. This study examined whether chronic light exposure alone, or in combination with TRF, modulates brown adipose tissue (BAT) in lean and obese mice. - Source: PubMed
Publication date: 2026/01/05
Oh EunseNah Ji YeonYun NaraeLee Mi NamPae Munkyong - The Bone Morphogenetic Protein (BMP) family acts as a critical modulator of cellular plasticity and lineage commitment in oncogenesis. However, the systematic contribution of BMP-related mRNAs (BRMs) to the progression and immunophenotypic landscape of kidney renal clear cell carcinoma (KIRC) remains poorly defined. - Source: PubMed
Publication date: 2026/06/06
Zhou YajieHu ZijianXie LeiZhang ShuwenHuang QiZhang NanLiu YijiangZhang WenxiongWang Kang - Temozolomide (TMZ) is used to treat glioblastoma cancer and it is essential to identify key genes and investigate the molecular mechanisms of glioblastoma cancer cells resistant to temozolomide. - Source: PubMed
Publication date: 2026/06/05
Alamholo MostafaTarinejad Alireza - Mesenchymal stromal cells from equine ovarian follicular aspirates represent a promising source for cell-based therapies. However, the age of the donor mare may alter their biological properties and therapeutic potential. This study aimed to evaluate the effect of age on MSCs from ovarian follicular aspirates of young (< 10 years, n = 5) and aged (≥ 18 years, n = 5) mares. MSCs were isolated, expanded, cryopreserved at passage 3, and subsequently thawed to evaluate proliferation, immunophenotype, differentiation capacity, and gene expression profiles. Proliferation rates, total cell yield, and mean time to reach 80% confluence showed no significant differences between the age groups. Flow cytometry analysis confirmed uniform expression of MSC-associated positive markers (CD90, CD29) and absence of CD45, CD19 and MHC-II in both groups. Trilineage differentiation assays demonstrated that cells retained trilineage differentiation capacity at a qualitative level regardless of donor age. However, transcriptomic analysis using RT Profiler PCR Array and qPCR validation revealed substantial differences in gene expression. MSCs from young mares exhibited significant upregulation (fold change ≥ 2; p < 0.05) of stemness-related genes (LIF, POU5F2), regulators of adipogenic and chondrogenic differentiation (PPARγ, SOX9), and cell migration-associated markers (MCAM, VCAM). Conversely, MSCs from young mares showed decreased expression (fold change ≤ 0.5; p < 0.05) of lineage-specific differentiation genes (TBX5, SLC2A4), inflammatory mediators (IL6), and senescence-associated markers (ITGAX, BMP4, SMAD3). These findings suggest that, although some MSC characteristics are preserved, donor age significantly alters the transcriptomic profile of equine follicular MSCs, which could affect their therapeutic efficacy. - Source: PubMed
Publication date: 2026/05/29
Muñoz-García C CSoriano-Campos M PLuis-Calero MGallardo-Soler AGonzález-Fernández LMacías-García B